Long-term outcomes of infliximab treatment in neuro-Behcet syndrome: A single-center retrospective study.

Introduction: Behcet's syndrome is a rare inflammatory disorder characterized by oral and genital ulcers, skin lesions, and uveitis. It exhibits a higher prevalence along the historic Silk Road. Neuro-Behcet syndrome (NBS) affects the central nervous system and poses significant morbidity and mortality risks. Infliximab, a TNF-alpha antagonist, has shown potential in NBS management, although the current evidence is mainly derived from case series due to the lack of randomized controlled trials. Objective: This retrospective study aimed to evaluate the disease outcomes during the first and second years following infliximab treatment in NBS patients experiencing attacks despite prior conventional immunosuppressive therapy. The study also sought to investigate the safety profile and adverse effects associated with infliximab. Methods: Fifty-three NBS patients were examined, with 22 receiving infliximab as either monotherapy or in combination with other therapies. Retrospective analysis was conducted on demographic data, clinical characteristics, and treatment responses. Treatment efficacy was measured using the Expanded Disability Status Scale (EDSS) modified for NBS. The study adhered to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklist guidelines. Results: Among the study cohort, 60.4% had parenchymal NBS, and 39.6% had nonparenchymal NBS. Treatment with infliximab resulted in remission or disease stabilization in 95% of patients after one year and 68.7% after 2 years. Relapse rates were 4.5% at 1 year and 18.7% at 2 years, with disease progression observed in two cases. Adverse effects were primarily mild to moderate, with no reports of serious adverse events. Conclusion: Infliximab exhibited efficacy in achieving remission or stabilization in NBS patients, maintaining a favorable safety profile. The timing of infliximab treatment may prevent the accumulation of disability and hinder disease progression. Nonetheless, future prospective studies are necessary to confirm these findings and refine treatment strategies for this complex condition. Key Points • Among the cohort of 53 patients diagnosed with Neuro-Behcet syndrome (NBS), parenchymal involvement was identified in 60.4% (n = 32), while non-parenchymal involvement was observed in 39.6% (n = 21) of cases. • Out of the 53 patients diagnosed with NBS, 20 individuals received a diagnosis of Behcet's syndrome upon their initial admission to our hospital due to central nervous system (CNS) involvement. • There were no discernible differences in the other clinical manifestations of Behcet syndrome between NBS patients requiring treatment with infliximab and those who did not necessitate such therapy. • Among patients with NBS who underwent treatment with ınfliximab, significant achievement of disease remission and stability was noted by the end of the second year, with noticeable prevention of disability accumulation and disease progression. [ABSTRACT FROM AUTHOR]